UB-311

Vaccine

Phase 2Amyloid-betaNo recent registered activity
Ungradedevidence

Evidence outlook

Mid- and late-stage studies completed

This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (2)
Early Alzheimer's Disease
Other / comorbidity
NCT03531710 · United Neuroscience Ltd.
2018-08-10 – 2019-10-31 · Alzheimer's Disease
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Early Alzheimer's Disease: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
UB-311: this drugPhase 2VaccineAmyloid-betanot yet gradedNo reviewed efficacy summary in this indication
BuntanetapPhase 3Small moleculeAPP/tau/alpha-synuclein/TDP-43 (translation)not yet gradedNo reviewed efficacy summary in this indication
AV-1959R
Phase 2(overall)
VaccineAmyloid-beta
Weak signal(overall)
No reviewed efficacy summary in this indication
ObicetrapibPhase 2Small moleculeCETPnot yet gradedNo reviewed efficacy summary in this indication
ACI-24.060
Phase 1/2(overall)
VaccineAmyloid-beta
not yet graded(overall)
No reviewed efficacy summary in this indication
Pepinemab
Phase 1/2(overall)
Monoclonal antibodySEMA4Dnot yet gradedNo reviewed efficacy summary in this indication
ALZ-101
Phase 1(overall)
VaccineAmyloid-beta
Partial signal(overall)
No reviewed efficacy summary in this indication
PMN310Phase 1Monoclonal antibodyAmyloid-beta (monoclonal antibody)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.